GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cinclus Pharma Holding AB (OSTO:CINPHA) » Definitions » Institutional Ownership

Cinclus Pharma Holding AB (OSTO:CINPHA) Institutional Ownership : 1.82% (As of May. 09, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Cinclus Pharma Holding AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cinclus Pharma Holding AB's institutional ownership is 1.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cinclus Pharma Holding AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cinclus Pharma Holding AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Cinclus Pharma Holding AB Institutional Ownership Historical Data

The historical data trend for Cinclus Pharma Holding AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cinclus Pharma Holding AB Institutional Ownership Chart

Cinclus Pharma Holding AB Historical Data

The historical data trend for Cinclus Pharma Holding AB can be seen below:

2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30
Institutional Ownership 3.02 2.62 1.99 1.43 1.67 1.36 1.36 1.36 1.82 1.82

Cinclus Pharma Holding AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cinclus Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a clinical stage pharmaceutical company developing a drug for the treatment of erosive gastroesophageal reflux diseases, and a dual therapy treatment with an antibiotic targeting Helicobacter pylori which is a bacteria that occurs in the gastric and duodenal mucosa. The Company's main target population is patients suffering from severe eGERD, where there is a lack of satisfactory treatment options.

Cinclus Pharma Holding AB Headlines

No Headlines